Journey Medical vs Fortress Biotech
DERM and FBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DERM and FBIO compare
Journey Medical is the larger company, worth 1.7 times as much as Fortress Biotech ($124M against $73.2M).
Journey Medical grew revenue faster over the last twelve months (17.0% versus 12.3% for Fortress Biotech).
Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 143% compared with −7.3% at Journey Medical.
Fortress Biotech scores higher on the StockData Score (9 against 7 for Journey Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DERM | FBIO |
|---|---|---|
| Size and price | ||
| Market cap | $124M | $73.2M |
| Share price | $4.39 | $1.99 |
| Change, 1 year | −51.5% | −25.7% |
| Change, 5 years | −50.1% | −95.7% |
| Beta (5Y) | 0.68 | 1.38 |
| Employees | 58 | 78 |
| StockData Score | ||
| Total score | 7 | 9 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 3 | 3 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.8× | 1.0× (better) |
| P/B | 3.8× | 0.5× (better) |
| Fair value | $5.78 | – |
| Margin of safety | 24.0% | – |
| Growth | ||
| Revenue growth (TTM) | 17.0% (better) | 12.3% |
| Revenue growth, 5Y average | 6.8% (better) | 6.8% |
| Net income growth (TTM) | – | 2411% |
| Profitability | ||
| Gross margin | 65.9% | 66.2% (better) |
| Operating margin | −2.9% (better) | −42.5% |
| Net margin | −7.3% | 143% (better) |
| Return on equity | −17.6% | 92.8% (better) |
| Return on invested capital | −5.2% (better) | −132% |
| Financial health | ||
| Debt / equity | 0.79 | 0.11 (better) |
| Interest coverage | −0.6× (better) | −3.2× |
| Current ratio | 1.48 | 2.93 (better) |
| Altman Z-score | 0.56 (better) | −2.23 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 37.8% | 15.9% |
| Held by insiders | 15.3% | 31.6% |
| Short interest, % of float | 12.9% | – |
Go deeper
- DERM stock overview
- DERM income statement
- DERM valuation and score
- FBIO stock overview
- FBIO income statement
- FBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.